Clinical significance of KL-6 in immune-checkpoint inhibitor treatment for non-small cell lung cancer
暂无分享,去创建一个
A. Sugimoto | H. Kaneda | T. Kawaguchi | K. Asai | Tetsuya Watanabe | S. Mitsuoka | M. Izumi | K. Ogawa | Y. Tani | K. Sawa | N. Yoshimoto | K. Nakahama | Hiroaki Nagamine | M. Fukui